| Biological Sciences | Lifetime | 619 | US 351 | 99.93 |
| Biological Sciences | 2021-2025 | 253 | US 50 | 99.75 |
| Molecular Medicine | Lifetime | 6 | US 2 | 99.88 |
| Clinical Pharmacology | Lifetime | 278 | US 120 | 98.87 |
| Endocrinology | Lifetime | 94 | US 43 | 98.66 |
| Applied Microbiology and Biotechnology | Lifetime | 30 | US 15 | 98.21 |
| Infectious Diseases | Lifetime | 862 | US 436 | 95.85 |
| Clinical Biochemistry | Lifetime | 307 | US 147 | 94.44 |
| Molecular Medicine | 2021-2025 | 3 | US 1 | 99.53 |
| Endocrinology | 2021-2025 | 10 | US 4 | 97.07 |
| Epidemiology | 2021-2025 | 325 | US 109 | 97.40 |
| Clinical Pharmacology | 2021-2025 | 235 | US 67 | 91.15 |
| Infectious Diseases | 2021-2025 | 563 | US 211 | 87.54 |
| Applied Microbiology and Biotechnology | 2021-2025 | 84 | US 26 | 85.67 |
| Antibiotic Resistance in Bacteria | Lifetime | 9 | US 3 | 99.95 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 9 | US 4 | 99.91 |
| Antibiotic Use and Resistance | Lifetime | 12 | US 4 | 99.86 |
| Vibrio bacteria research studies | Lifetime | 14 | US 10 | 99.82 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 50 | US 23 | 99.64 |
| Bacterial biofilms and quorum sensing | Lifetime | 58 | US 25 | 99.51 |
| Pharmaceutical and Antibiotic Environmental Impacts | Lifetime | 78 | US 14 | 99.52 |
| Urinary Tract Infections Management | Lifetime | 115 | US 61 | 98.99 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 155 | US 70 | 98.94 |
| Infections and bacterial resistance | Lifetime | 20 | US 5 | 99.12 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 37 | US 11 | 98.63 |
| Pneumonia and Respiratory Infections | Lifetime | 289 | US 120 | 98.94 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 314 | US 142 | 98.50 |
| Tuberculosis Research and Epidemiology | Lifetime | 731 | US 227 | 97.56 |
| Phenothiazines and Benzothiazines Synthesis and Activities | Lifetime | 272 | US 60 | 95.91 |
| Mycobacterium research and diagnosis | Lifetime | 925 | US 297 | 96.20 |
| Escherichia coli research studies | Lifetime | 499 | US 196 | 96.32 |
| Nosocomial Infections in ICU | Lifetime | 451 | US 156 | 95.86 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 201 | US 52 | 87.27 |
| Infection Control in Healthcare | Lifetime | 803 | US 333 | 82.87 |
| Burkholderia infections and melioidosis | Lifetime | 488 | US 97 | 80.12 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 7 | US 2 | 99.75 |
| Vibrio bacteria research studies | 2021-2025 | 4 | US 1 | 98.45 |
| Infections and bacterial resistance | 2021-2025 | 2 | US 1 | 98.50 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 21 | US 6 | 99.01 |
| Antibiotic Use and Resistance | 2021-2025 | 32 | US 9 | 98.67 |
| Pneumonia and Respiratory Infections | 2021-2025 | 88 | US 24 | 97.36 |
| Urinary Tract Infections Management | 2021-2025 | 55 | US 29 | 96.00 |
| Bacterial biofilms and quorum sensing | 2021-2025 | 75 | US 13 | 96.27 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 116 | US 28 | 95.80 |
| Mycobacterium research and diagnosis | 2021-2025 | 267 | US 77 | 92.43 |
| Tuberculosis Research and Epidemiology | 2021-2025 | 427 | US 98 | 94.23 |
| Appendicitis Diagnosis and Management | 2021-2025 | 202 | US 51 | 89.96 |
| Bacteriophages and microbial interactions | 2021-2025 | 574 | US 131 | 90.11 |
| Escherichia coli research studies | 2021-2025 | 146 | US 32 | 87.81 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 444 | US 84 | 87.75 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 391 | US 97 | 87.02 |
| Diverticular Disease and Complications | 2021-2025 | 301 | US 80 | 86.40 |
| Bacterial Infections and Vaccines | 2021-2025 | 443 | US 100 | 81.70 |
| Cancer therapeutics and mechanisms | 2021-2025 | 508 | US 113 | 80.88 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 114 | US 9 | 78.73 |
| Bacterial Genetics and Biotechnology | 2021-2025 | 676 | US 202 | 77.46 |
| Nosocomial Infections in ICU | 2021-2025 | 809 | US 140 | 70.09 |
| Quinazolinone synthesis and applications | 2021-2025 | 488 | US 24 | 66.93 |
| Phenothiazines and Benzothiazines Synthesis and Activities | 2021-2025 | 528 | US 24 | 60.92 |
| Burkholderia infections and melioidosis | 2021-2025 | 600 | US 81 | 27.37 |